<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03728335</url>
  </required_header>
  <id_info>
    <org_study_id>18117</org_study_id>
    <secondary_id>NCI-2018-02371</secondary_id>
    <secondary_id>18117</secondary_id>
    <nct_id>NCT03728335</nct_id>
  </id_info>
  <brief_title>Enasidenib as Maintenance Therapy in Treating Patients With Acute Myeloid Leukemia With IDH2 Mutation After Donor Stem Cell Transplant</brief_title>
  <official_title>Pilot Trial of Enasidenib (AG-221) Maintenance Post Allogeneic Hematopoietic Cell Transplantation in Patients With IDH2 Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects of using enasidenib as maintenance therapy in&#xD;
      treating patients with acute myeloid leukemia with IDH2 mutation following donor stem cell&#xD;
      transplant. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes&#xD;
      needed for cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate the safety and tolerability of enasidenib mesylate as maintenance therapy in post&#xD;
      hematopoietic cell transplantation (HCT) patients.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Assess overall and leukemia free survival in patients post allogeneic HCT. II. Estimate&#xD;
      relapse incidence, non-relapse mortality, graft versus host disease (GVHD) and relapse free&#xD;
      survival (GRFS) in patients receiving enasidenib mesylate maintenance therapy.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Monitor disease status among subset of patients with minimal residual disease (MRD)&#xD;
      positive disease when starting to receive enasidenib mesylate by multiparameter flow&#xD;
      cytometry post allogeneic HCT on patients bone marrow (BM) on days +100 and +365.&#xD;
&#xD;
      II. Investigate clearance of IDH2 mutation post HCT by next generation sequencing-polymerase&#xD;
      chain reaction (NGS-PCR) testing on the bone marrow specimens on days +100 and +365 and in&#xD;
      peripheral blood every 3 months till 2 year follow up.&#xD;
&#xD;
      III. Investigate mIDH2 variant allele fraction (VAF) by droplet digital PCR (ddPCR) BEAMing&#xD;
      technology on bone marrow specimens on days +100 and +365.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive enasidenib orally (PO) once daily (QD) on days 1-28. Treatment repeats every&#xD;
      28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 30 days and periodically&#xD;
      thereafter up to 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 11, 2019</start_date>
  <completion_date type="Anticipated">December 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Up to 30 days post treatment completion</time_frame>
    <description>Toxicity will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From starting enasidenib to date of death, assessed up to 2 years</time_frame>
    <description>Will be analyzed using the Kaplan-Meier curves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia free survival (LFS)</measure>
    <time_frame>From starting enasidenib to date of relapse or death, assessed up to 2 years</time_frame>
    <description>Will be analyzed using the Kaplan-Meier curves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>From starting enasidenib to date of relapse, assessed up to 2 years</time_frame>
    <description>Time to relapse will be censored at the last disease assessment if patients are known to be alive and leukemia free.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality (NRM)</measure>
    <time_frame>From starting enasidenib to date of death from other causes than relapse, assessed up to 2 years</time_frame>
    <description>Will be analyzed using the curves of cumulative incidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft versus host disease (GvHD)-free relapse free survival (GRFS)</measure>
    <time_frame>At 1 year mark of starting enasidenib</time_frame>
    <description>Will be analyzed using the Kaplan-Meier curves.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Minimal residual disease (MRD) disappearance (bone marrow [BM])</measure>
    <time_frame>At days 100 and 365</time_frame>
    <description>Monitor disease status among subset of patients with MRD positive disease by multiparameter flow cytometry post allogeneic hematopoietic cell transplantation (HCT) on patients BM.</description>
  </other_outcome>
  <other_outcome>
    <measure>IDH2 mutation clearance (BM and peripheral blood)</measure>
    <time_frame>At days 100 and 365 and up to 2 years</time_frame>
    <description>Investigate clearance of IDH2 mutation post HCT by next generation sequencing-polymerase chain reaction (NGS-PCR) testing on the bone marrow specimens.</description>
  </other_outcome>
  <other_outcome>
    <measure>mIDH2 variant allele fraction (BM)</measure>
    <time_frame>At days 100 and 365</time_frame>
    <description>mIDH2 variant allele fraction (VAF) by droplet digital PCR (ddPCR) BEAMing technology on bone marrow specimens.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (enasidenib mesylate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive enasidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enasidenib Mesylate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (enasidenib mesylate)</arm_group_label>
    <other_name>2-Methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol Methanesulfonate</other_name>
    <other_name>2-Propanol, 2-Methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-, Methanesulfonate (1:1)</other_name>
    <other_name>AG-221 Mesylate</other_name>
    <other_name>CC-90007</other_name>
    <other_name>Enasidenib Methanesulfonate</other_name>
    <other_name>Idhifa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented informed consent of the participant and/or legally authorized&#xD;
             representative&#xD;
&#xD;
          -  Agreement to allow the use of archival tissue from diagnostic tumor biopsies&#xD;
&#xD;
               -  If unavailable, exceptions may be granted with study principal investigator (PI)&#xD;
                  approval&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) =&lt; 2 or Karnofsky performance status (KPS)&#xD;
             &gt;= 70&#xD;
&#xD;
          -  Recipients of allogeneic HCT - all stem cell sources including sibling, unrelated,&#xD;
             mismatched related/unrelated, cord and haploidentical transplant patients will be&#xD;
             included&#xD;
&#xD;
          -  Conditioning regimen: Investigator's choice based on center guidelines&#xD;
&#xD;
          -  GvHD prophylaxis: sirolimus + tacrolimus or tacrolimus + methotrexate or investigator&#xD;
             choice&#xD;
&#xD;
          -  Patients must have acute myeloid leukemia (AML) with IDH2 mutation at diagnosis. Day&#xD;
             30 marrow post HCT should show evidence of morphologic remission with &lt; 5% bone marrow&#xD;
             blasts. Patients with MRD either by flow cytometry or IDH2 mutation testing will be&#xD;
             allowed&#xD;
&#xD;
          -  Patients with previous therapy with IDH2 inhibitors will be included&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt; 1000 (performed within 28 days prior to day 1 of&#xD;
             protocol therapy unless otherwise stated)&#xD;
&#xD;
          -  Hemoglobin &gt;= 9.5 gm% (performed within 28 days prior to day 1 of protocol therapy&#xD;
             unless otherwise stated)&#xD;
&#xD;
          -  Platelets &gt; 50,000/mm^3 (performed within 28 days prior to day 1 of protocol therapy&#xD;
             unless otherwise stated)&#xD;
&#xD;
          -  Platelets &gt;= 20,000/mm^3 (performed within 28 days prior to day 1 of protocol therapy&#xD;
             unless otherwise stated)&#xD;
&#xD;
               -  NOTE: Patients with lower counts can enroll if infection cytomegalovirus&#xD;
                  (CMV)/human herpesvirus 6 (HHV6) etc. is being treated actively&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease)&#xD;
             (performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)&#xD;
&#xD;
          -  Total bilirubin &lt; 2.0 mg/dl-exception permitted in patients with Gilbert's Syndrome&#xD;
             (performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)&#xD;
&#xD;
          -  Aspartate aminotransferases (AST) (serum glutamic-oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 2 x ULN, patients with abnormal liver function tests (LFTs) in the context of&#xD;
             active GVHD will not be included (performed within 28 days prior to day 1 of protocol&#xD;
             therapy unless otherwise stated)&#xD;
&#xD;
          -  Creatinine clearance of &gt;= 40/min/1.73 m^2 for participants with creatinine levels&#xD;
             above institutional normal per 24 hour urine test or the Cockcroft-Gault formula&#xD;
             (performed within 28 days prior to day 1 of protocol therapy unless otherwise stated)&#xD;
&#xD;
          -  Corrected QT (QTc) =&lt; 480 ms&#xD;
&#xD;
               -  Note: To be performed within 28 days prior to day 1 of protocol therapy&#xD;
&#xD;
          -  Seronegative for human immunodeficiency virus (HIV) antigen/antibody (Ag/Ab) combo,&#xD;
             hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen negative),&#xD;
             and syphilis (rapid plasma reagin [RPR])&#xD;
&#xD;
               -  If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP): negative urine or serum pregnancy test&#xD;
&#xD;
               -  If the urine test is positive or cannot be confirmed as negative, a serum&#xD;
                  pregnancy test will be required&#xD;
&#xD;
          -  Agreement by females and males of childbearing potential to use an effective method of&#xD;
             birth control or abstain from heterosexual activity for the course of the study&#xD;
             through at least 3 months after the last dose of protocol therapy&#xD;
&#xD;
               -  Childbearing potential defined as not being surgically sterilized (men and women)&#xD;
                  or have not been free from menses for &gt; 1 year (women only)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to study agent&#xD;
&#xD;
          -  Active diarrhea considered clinically significant and may impair oral drug&#xD;
             administration&#xD;
&#xD;
          -  Clinically significant uncontrolled illness&#xD;
&#xD;
          -  Active infection requiring antibiotics&#xD;
&#xD;
               -  Active infection. Patients with treated viral, bacterial or fungal infections&#xD;
                  that are controlled on therapy will be allowed to participate&#xD;
&#xD;
          -  Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection&#xD;
&#xD;
          -  Diagnosis of Gilbert's disease&#xD;
&#xD;
          -  Other active malignancy. Participants with history of prior malignancy treated with&#xD;
             curative intent who achieved complete response (CR) more than 2 years before study&#xD;
             entry are eligible. This exclusion rule does not apply to non-melanoma skin tumors and&#xD;
             in-situ cervical cancer&#xD;
&#xD;
          -  Females only: Pregnant or breastfeeding&#xD;
&#xD;
          -  Active grade II-IV acute GVHD and/or requiring systemic steroids with prednisone dose&#xD;
             equivalent of &gt;= 0.25 mg/kg at end of 4 weeks&#xD;
&#xD;
          -  Any other condition that would, in the investigator's judgment, contraindicate the&#xD;
             patient's participation in the clinical study due to safety concerns with clinical&#xD;
             study procedures&#xD;
&#xD;
          -  Prospective participants, who, in the opinion of the investigator, may not be able to&#xD;
             comply with all study procedures (including compliance issues related to&#xD;
             feasibility/logistics)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amandeep Salhotra</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amandeep Salhotra</last_name>
      <phone>626-218-2405</phone>
      <email>asalhotra@coh.org</email>
    </contact>
    <investigator>
      <last_name>Amandeep Salhotra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelli Bejanyan</last_name>
      <phone>612-625-8942</phone>
      <email>nbejanya@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Nelli Bejanyan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 31, 2018</study_first_submitted>
  <study_first_submitted_qc>October 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2018</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

